Akebia Therapeutics (AKBA) Accumulated Expenses (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Accumulated Expenses data on file, last reported at $125.1 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $125.1 million, up 75.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $125.1 million (up 75.31% YoY), and the FY2025 annual result was $121.7 million, up 91.8% from the prior year.
• Accumulated Expenses improved to $125.1 million in Q1 2026 per AKBA's latest filing, from $121.7 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $125.1 million in Q1 2026 and troughed at $51.1 million in Q1 2023.
• A 5-year average of $79.7 million and a median of $71.3 million in 2025 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2023 and 2025: Accumulated Expenses sank 55.29% in 2023, then surged 103.81% in 2025.
• A 5-year view of Accumulated Expenses shows it stood at $75.8 million in 2022, then fell by 10.61% to $67.7 million in 2023, then decreased by 6.31% to $63.5 million in 2024, then soared by 91.8% to $121.7 million in 2025, then advanced by 2.75% to $125.1 million in 2026.
• Business Quant data shows AKBA's Accumulated Expenses at $125.1 million in Q1 2026, $121.7 million in Q4 2025, and $106.4 million in Q3 2025.